Sartorius Stedim Biotech Statistics
Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of EUR 17.91 billion. The enterprise value is 20.41 billion.
Market Cap | 17.91B |
Enterprise Value | 20.41B |
Important Dates
The next estimated earnings date is Thursday, October 17, 2024.
Earnings Date | Oct 17, 2024 |
Ex-Dividend Date | Apr 2, 2024 |
Share Statistics
Sartorius Stedim Biotech has 97.31 million shares outstanding. The number of shares has increased by 2.62% in one year.
Shares Outstanding | 97.31M |
Shares Change (YoY) | +2.62% |
Shares Change (QoQ) | +1.07% |
Owned by Insiders (%) | 0.00% |
Owned by Institutions (%) | 13.00% |
Float | 29.47M |
Valuation Ratios
The trailing PE ratio is 102.32 and the forward PE ratio is 44.83. Sartorius Stedim Biotech's PEG ratio is 2.12.
PE Ratio | 102.32 |
Forward PE | 44.83 |
PS Ratio | 6.31 |
PB Ratio | 4.51 |
P/FCF Ratio | 58.71 |
PEG Ratio | 2.12 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.15, with an EV/FCF ratio of 66.91.
EV / Earnings | 120.39 |
EV / Sales | 7.43 |
EV / EBITDA | 30.15 |
EV / EBIT | 48.95 |
EV / FCF | 66.91 |
Financial Position
The company has a current ratio of 1.94, with a Debt / Equity ratio of 74.38.
Current Ratio | 1.94 |
Quick Ratio | 0.95 |
Debt / Equity | 74.38 |
Debt / EBITDA | 4.31 |
Debt / FCF | 9.57 |
Interest Coverage | 2.47 |
Financial Efficiency
Return on equity (ROE) is 5.31% and return on invested capital (ROIC) is 4.82%.
Return on Equity (ROE) | 5.31% |
Return on Assets (ROA) | 3.93% |
Return on Capital (ROIC) | 4.82% |
Revenue Per Employee | 264,583 |
Profits Per Employee | 16,326 |
Employee Count | 10,382 |
Asset Turnover | 0.41 |
Inventory Turnover | 1.71 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.43% in the last 52 weeks. The beta is 0.66, so Sartorius Stedim Biotech's price volatility has been lower than the market average.
Beta (5Y) | 0.66 |
52-Week Price Change | -88.43% |
50-Day Moving Average | 167.93 |
200-Day Moving Average | 211.32 |
Relative Strength Index (RSI) | 63.70 |
Average Volume (20 Days) | 46,738 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of EUR 2.75 billion and earned 169.50 million in profits. Earnings per share was 1.80.
Revenue | 2.75B |
Gross Profit | 1.19B |
Operating Income | 416.90M |
Pretax Income | 236.40M |
Net Income | 169.50M |
EBITDA | 651.90M |
EBIT | 416.90M |
Earnings Per Share (EPS) | 1.80 |
Balance Sheet
The company has 454.10 million in cash and 2.92 billion in debt, giving a net cash position of -2.46 billion or -25.33 per share.
Cash & Cash Equivalents | 454.10M |
Total Debt | 2.92B |
Net Cash | -2.46B |
Net Cash Per Share | -25.33 |
Equity (Book Value) | 3.92B |
Book Value Per Share | 40.84 |
Working Capital | 823.80M |
Cash Flow
In the last 12 months, operating cash flow was 706.10 million and capital expenditures -401.10 million, giving a free cash flow of 305.00 million.
Operating Cash Flow | 706.10M |
Capital Expenditures | -401.10M |
Free Cash Flow | 305.00M |
FCF Per Share | 3.13 |
Margins
Gross margin is 43.16%, with operating and profit margins of 15.18% and 6.17%.
Gross Margin | 43.16% |
Operating Margin | 15.18% |
Pretax Margin | 8.61% |
Profit Margin | 6.17% |
EBITDA Margin | 23.73% |
EBIT Margin | 15.18% |
FCF Margin | 11.10% |
Dividends & Yields
This stock pays an annual dividend of 0.69, which amounts to a dividend yield of 0.38%.
Dividend Per Share | 0.69 |
Dividend Yield | 0.38% |
Dividend Growth (YoY) | -52.08% |
Years of Dividend Growth | 3 |
Payout Ratio | 39.59% |
Buyback Yield | -2.62% |
Shareholder Yield | -2.24% |
Earnings Yield | 0.98% |
FCF Yield | 1.70% |
Stock Splits
The last stock split was on May 6, 2016. It was a forward split with a ratio of 6.
Last Split Date | May 6, 2016 |
Split Type | Forward |
Split Ratio | 6 |